142 related articles for article (PubMed ID: 31189812)
1. [Effect of Hypoalbuminemia on Severe Neutropenia Induced by Paclitaxel Monotherapy and Paclitaxel plus Ramucirumab Combination Therapy in Patients with Gastric Cancer].
Nakazawa Y; Kageyama A; Harada D; Kitamura M; Mitsumori N; Kawakubo T
Gan To Kagaku Ryoho; 2019 May; 46(5):901-905. PubMed ID: 31189812
[TBL] [Abstract][Full Text] [Related]
2. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
[TBL] [Abstract][Full Text] [Related]
4. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of Neutropenia and Usages of Antihypertensive Drugs in Patients Treated with Ramucirumab plus Paclitaxel Therapy].
Kawaguchi M; Kawakami K; Aoyama T; Tomomatsu T; Hama T; Takahari D; Chin K; Yamaguchi K; Yamaguchi M
Gan To Kagaku Ryoho; 2022 Aug; 49(8):873-878. PubMed ID: 36046973
[TBL] [Abstract][Full Text] [Related]
6. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
Kimura M; Usami E; Teramachi H; Yoshimura T
J Oncol Pharm Pract; 2018 Sep; 24(6):403-411. PubMed ID: 28436252
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer.
Hayase S; Yamada L; Ujiie D; Nirei A; Tada T; Hanayama H; Monma T; Saze Z; Ohki S; Kono K
Fukushima J Med Sci; 2019; 65(1):6-12. PubMed ID: 30996218
[TBL] [Abstract][Full Text] [Related]
9. [A Case of Recurrent Gastric Cancer with Grade 3 Proteinuria Caused by Ramucirumab plus Paclitaxel Therapy].
Kimura Y; Makari Y; Mikami J; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Imano M; Imamoto H; Fujita J; Furukawa H; Yasuda T
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1080-1082. PubMed ID: 29394540
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Efficacy and Safety of Nab-Paclitaxel plus Ramucirumab Therapy in Patients with Unresectable Advanced or Recurrent Gastric Cancer].
Murakami K; Takeno A; Masuzawa T; Imada A; Takase K; Toya K; Yukawa Y; Kawai K; Sakamoto T; Katsura Y; Ohmura Y; Kagawa Y; Hata T; Takeda Y; Murata K
Gan To Kagaku Ryoho; 2020 Mar; 47(3):493-495. PubMed ID: 32381926
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and Safety of Paclitaxel plus Ramucirumab Therapy for Unresectable or Recurrent Gastric Cancer].
Tsujio G; Toyokawa T; Fukuoka T; Tamura T; Ohira G; Shibutani M; Yamazoe S; Nagahara H; Kimura K; Amano R; Tanaka H; Muguruma K; Yashiro M; Maeda K; Hirakawa K; Ohira M
Gan To Kagaku Ryoho; 2019 May; 46(5):895-899. PubMed ID: 31189811
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
Jung M; Ryu MH; Oh DY; Kang M; Zang DY; Hwang IG; Lee KW; Kim KH; Shim BY; Song EK; Sym SJ; Han HS; Park YL; Kim JS; Lee HW; Lee MH; Koo DH; Song HS; Lee N; Yang SH; Choi DR; Hong YS; Lee KE; Maeng CH; Baek JH; Kim S; Kim YH; Rha SY; Cho JY; Kang YK
Gastric Cancer; 2018 Sep; 21(5):819-830. PubMed ID: 29427038
[TBL] [Abstract][Full Text] [Related]
13. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
14. Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study.
Nara K; Yamamoto T; Yamashita H; Yagi K; Takada T; Seto Y; Suzuki H
BMC Cancer; 2023 Oct; 23(1):979. PubMed ID: 37833660
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy.
Kakuta T; Yabusaki H; Bamba T; Aizawa M; Nogami H; Nomura T; Matsuki A; Maruyama S; Takii Y; Nakagawa S
Int J Clin Oncol; 2021 Apr; 26(4):684-693. PubMed ID: 33389346
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the safety of ramucirumab in Japanese patients with advanced gastric cancer.
Iwai M; Ito D; Asano H; Adachi S; Okada K; Kimura M; Usami E; Matsuo K; Yoshimura T; Teramachi H
Pharmazie; 2018 May; 73(5):309-312. PubMed ID: 29724300
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study.
Hagiwara Y; Nakasya A; Matsumoto T; Ikoma T; Yamamoto Y; Kurioka Y; Tsuduki T; Kajiwara T; Nishina T; Yamashita N; Moriwaki T; Hyodo I
J Gastrointest Oncol; 2022 Dec; 13(6):2769-2778. PubMed ID: 36636083
[TBL] [Abstract][Full Text] [Related]
18. [Identification of the Risk Factors for Cabazitaxel-Induced Neutropenia with Preventive Administration of Pegfilgrastim].
Kageyama A; Nakazawa Y; Ando N; Harada D; Kitamura M; Kawakubo T; Asano K
Gan To Kagaku Ryoho; 2019 Feb; 46(2):279-281. PubMed ID: 30914534
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
